Efficient NQO1 substrates are potent and selective anticancer agents

Elizabeth I. Parkinson, Joseph S. Bair, Megan Cismesia, Paul J. Hergenrother

Research output: Contribution to journalArticle

Abstract

A major goal of personalized medicine in oncology is the identification of drugs with predictable efficacy based on a specific trait of the cancer cell, as has been demonstrated with gleevec (presence of Bcr-Abl protein), herceptin (Her2 overexpression), and iressa (presence of a specific EGFR mutation). This is a challenging task, as it requires identifying a cellular component that is altered in cancer, but not normal cells, and discovering a compound that specifically interacts with it. The enzyme NQO1 is a potential target for personalized medicine, as it is overexpressed in many solid tumors. In normal cells NQO1 is inducibly expressed, and its major role is to detoxify quinones via bioreduction; however, certain quinones become more toxic after reduction by NQO1, and these compounds have potential as selective anticancer agents. Several quinones of this type have been reported, including mitomycin C, RH1, EO9, streptonigrin, β-lapachone, and deoxynyboquinone (DNQ). However, no unified picture has emerged from these studies, and the key question regarding the relationship between NQO1 processing and anticancer activity remains unanswered. Here, we directly compare these quinones as substrates for NQO1 in vitro, and for their ability to kill cancer cells in culture in an NQO1-dependent manner. We show that DNQ is a superior NQO1 substrate, and we use computationally guided design to create DNQ analogues that have a spectrum of activities with NQO1. Assessment of these compounds definitively establishes a strong relationship between in vitro NQO1 processing and induction of cancer cell death and suggests these compounds are outstanding candidates for selective anticancer therapy.

Original languageEnglish (US)
Pages (from-to)2173-2183
Number of pages11
JournalACS chemical biology
Volume8
Issue number10
DOIs
StatePublished - Oct 18 2013

Fingerprint

Quinones
Antineoplastic Agents
apaziquone
Substrates
Precision Medicine
Medicine
Neoplasms
Streptonigrin
Cells
Oncology
Poisons
Bioelectric potentials
Mitomycin
Cell death
Processing
Cell culture
Tumors
Cell Death
Cell Culture Techniques
Enzymes

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine

Cite this

Efficient NQO1 substrates are potent and selective anticancer agents. / Parkinson, Elizabeth I.; Bair, Joseph S.; Cismesia, Megan; Hergenrother, Paul J.

In: ACS chemical biology, Vol. 8, No. 10, 18.10.2013, p. 2173-2183.

Research output: Contribution to journalArticle

Parkinson, Elizabeth I. ; Bair, Joseph S. ; Cismesia, Megan ; Hergenrother, Paul J. / Efficient NQO1 substrates are potent and selective anticancer agents. In: ACS chemical biology. 2013 ; Vol. 8, No. 10. pp. 2173-2183.
@article{4088d74ad6274d65b1fb4ae90950020e,
title = "Efficient NQO1 substrates are potent and selective anticancer agents",
abstract = "A major goal of personalized medicine in oncology is the identification of drugs with predictable efficacy based on a specific trait of the cancer cell, as has been demonstrated with gleevec (presence of Bcr-Abl protein), herceptin (Her2 overexpression), and iressa (presence of a specific EGFR mutation). This is a challenging task, as it requires identifying a cellular component that is altered in cancer, but not normal cells, and discovering a compound that specifically interacts with it. The enzyme NQO1 is a potential target for personalized medicine, as it is overexpressed in many solid tumors. In normal cells NQO1 is inducibly expressed, and its major role is to detoxify quinones via bioreduction; however, certain quinones become more toxic after reduction by NQO1, and these compounds have potential as selective anticancer agents. Several quinones of this type have been reported, including mitomycin C, RH1, EO9, streptonigrin, β-lapachone, and deoxynyboquinone (DNQ). However, no unified picture has emerged from these studies, and the key question regarding the relationship between NQO1 processing and anticancer activity remains unanswered. Here, we directly compare these quinones as substrates for NQO1 in vitro, and for their ability to kill cancer cells in culture in an NQO1-dependent manner. We show that DNQ is a superior NQO1 substrate, and we use computationally guided design to create DNQ analogues that have a spectrum of activities with NQO1. Assessment of these compounds definitively establishes a strong relationship between in vitro NQO1 processing and induction of cancer cell death and suggests these compounds are outstanding candidates for selective anticancer therapy.",
author = "Parkinson, {Elizabeth I.} and Bair, {Joseph S.} and Megan Cismesia and Hergenrother, {Paul J.}",
year = "2013",
month = "10",
day = "18",
doi = "10.1021/cb4005832",
language = "English (US)",
volume = "8",
pages = "2173--2183",
journal = "ACS Chemical Biology",
issn = "1554-8929",
publisher = "American Chemical Society",
number = "10",

}

TY - JOUR

T1 - Efficient NQO1 substrates are potent and selective anticancer agents

AU - Parkinson, Elizabeth I.

AU - Bair, Joseph S.

AU - Cismesia, Megan

AU - Hergenrother, Paul J.

PY - 2013/10/18

Y1 - 2013/10/18

N2 - A major goal of personalized medicine in oncology is the identification of drugs with predictable efficacy based on a specific trait of the cancer cell, as has been demonstrated with gleevec (presence of Bcr-Abl protein), herceptin (Her2 overexpression), and iressa (presence of a specific EGFR mutation). This is a challenging task, as it requires identifying a cellular component that is altered in cancer, but not normal cells, and discovering a compound that specifically interacts with it. The enzyme NQO1 is a potential target for personalized medicine, as it is overexpressed in many solid tumors. In normal cells NQO1 is inducibly expressed, and its major role is to detoxify quinones via bioreduction; however, certain quinones become more toxic after reduction by NQO1, and these compounds have potential as selective anticancer agents. Several quinones of this type have been reported, including mitomycin C, RH1, EO9, streptonigrin, β-lapachone, and deoxynyboquinone (DNQ). However, no unified picture has emerged from these studies, and the key question regarding the relationship between NQO1 processing and anticancer activity remains unanswered. Here, we directly compare these quinones as substrates for NQO1 in vitro, and for their ability to kill cancer cells in culture in an NQO1-dependent manner. We show that DNQ is a superior NQO1 substrate, and we use computationally guided design to create DNQ analogues that have a spectrum of activities with NQO1. Assessment of these compounds definitively establishes a strong relationship between in vitro NQO1 processing and induction of cancer cell death and suggests these compounds are outstanding candidates for selective anticancer therapy.

AB - A major goal of personalized medicine in oncology is the identification of drugs with predictable efficacy based on a specific trait of the cancer cell, as has been demonstrated with gleevec (presence of Bcr-Abl protein), herceptin (Her2 overexpression), and iressa (presence of a specific EGFR mutation). This is a challenging task, as it requires identifying a cellular component that is altered in cancer, but not normal cells, and discovering a compound that specifically interacts with it. The enzyme NQO1 is a potential target for personalized medicine, as it is overexpressed in many solid tumors. In normal cells NQO1 is inducibly expressed, and its major role is to detoxify quinones via bioreduction; however, certain quinones become more toxic after reduction by NQO1, and these compounds have potential as selective anticancer agents. Several quinones of this type have been reported, including mitomycin C, RH1, EO9, streptonigrin, β-lapachone, and deoxynyboquinone (DNQ). However, no unified picture has emerged from these studies, and the key question regarding the relationship between NQO1 processing and anticancer activity remains unanswered. Here, we directly compare these quinones as substrates for NQO1 in vitro, and for their ability to kill cancer cells in culture in an NQO1-dependent manner. We show that DNQ is a superior NQO1 substrate, and we use computationally guided design to create DNQ analogues that have a spectrum of activities with NQO1. Assessment of these compounds definitively establishes a strong relationship between in vitro NQO1 processing and induction of cancer cell death and suggests these compounds are outstanding candidates for selective anticancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=84886519739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886519739&partnerID=8YFLogxK

U2 - 10.1021/cb4005832

DO - 10.1021/cb4005832

M3 - Article

C2 - 23937670

AN - SCOPUS:84886519739

VL - 8

SP - 2173

EP - 2183

JO - ACS Chemical Biology

JF - ACS Chemical Biology

SN - 1554-8929

IS - 10

ER -